Japan Grants First Global Approval to GSK's Hibsago as a Functional Cure for Chronic Hepatitis B
GSK sits 34% above its 52-week low of $38.63.
Summary
GSK's bepirovirsen (Hibsago) received its first global approval in Japan as the first and only functional cure for chronic hepatitis B, supported by Phase 3 data showing a 19% functional cure rate versus 1% for standard of care.
Key Events · Product Development and Regulatory · GSK
-
First Global Approval for Hibsago
Japan's MHLW approved Hibsago (bepirovirsen) as the first and only functional cure for chronic hepatitis B in adults meeting specific viral marker criteria.
-
Phase 3 Efficacy Data
B-Well trials showed a 19% functional cure rate (233 of 1,220) versus 0% for placebo, compared to ~1% for standard of care; 26% cure rate in the ≤1000 IU/ml HBsAg subgroup.
-
Accelerated SENKU Designation
Approval was accelerated by Japan's SENKU designation for innovative medicines addressing high unmet medical need.
-
US Regulatory Decision Pending
GSK expects US regulatory decisions for bepirovirsen in the coming months, with submissions advancing across multiple geographies.
Analysis · GSK · Life Sciences
Japan's MHLW has approved Hibsago (bepirovirsen) as the first and only functional cure for chronic hepatitis B, marking the drug's first global regulatory approval. The decision is backed by Phase 3 B-Well data showing a 19% functional cure rate versus 1% for standard of care, and was accelerated by Japan's SENKU designation for high unmet need. With nearly one million people living with CHB in Japan and US regulatory decisions expected in the coming months, this approval validates a potential blockbuster franchise and de-risks the broader global regulatory pathway.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 44% of the 972 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GSK was trading at $51.83 on NYSE in the Life Sciences sector, with a market capitalization of approximately $104.9B. The 52-week trading range was $38.63 to $61.70. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.